登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TRAIL R1】

TRAIL R1信息

英文名称:Tumor necrosis factor receptor superfamily member 10A
中文名称:肿瘤坏死因子受体超家族成员10A
靶点别称:TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,TRAILR-1,CD261,TNF-related apoptosis-inducing ligand receptor 1,Tumor Necrosis Factor Receptor Superfamily Member 10a Variant 2
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

TRAIL R1产品列表

产品库
物种
属性
ACRO质量管理体系
 
评论(0)
 

TRAIL R1分子别名

TNFRSF10A,TRAIL-R1,CD261,APO2,DR4

TRAIL R1分子背景

Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

TRAIL R1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

TRAIL R1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定